Lupron: Clinical Trials

50 trials of Lupron, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 10 active not recruiting, 8 recruiting, 4 terminated. 50 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 250Completed 25, Active not recruiting 10, Recruiting 8, Terminated 4, Withdrawn 2, Unknown 1
Phase 12Completed 1, Terminated 1
Phase 31Active not recruiting 1

Follow Lupron: new trials by email Literature Review of Lupron trials Research Report on Lupron

Trials (filtered) newest first · largest first

All 50 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2RecruitingMayo Clinic2022026-08-042026-09-18
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma
Phase 2RecruitingBaptist Health South Florida502026-07-292026-08-06
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Darolutamide, Pembrolizumab, Lupron - Prostate Cancer, High-risk Prostate Cancer
Phase 2RecruitingIcahn School of Medicine at Mount Sinai402026-05-212026-10-07
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer
Phase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins602026-03-092026-03-11
The COSMYC Trial (COmbined Suppression of MYC)
ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer
Phase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins502025-08-192026-10-30
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Biospecimen Collection, Chest Radiography, Computed Tomography - Adult Ovarian Granulosa Cell Tumor
Phase 2CompletedNational Cancer Institute (NCI)172024-02-082026-11-03
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer
Phase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins502023-10-042026-01-14
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)202023-07-202026-11-16
RElugolix VErsus LeUprolide Cardiac Trial
Radiation therapy, Leuprolide, Relugolix - Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
Phase 2Active not recruitingEmory University942022-06-062026-02-12
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Abiraterone Acetate, Bicalutamide, Degarelix - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 2RecruitingCity of Hope Medical Center702021-05-042026-01-28
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Abiraterone Acetate, Apalutamide, Leuprolide Acetate - Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation
Phase 2Active not recruitingJonsson Comprehensive Cancer Center282021-03-172026-02-05
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 2WithdrawnM.D. Anderson Cancer Center2020-11-242021-01-20
Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer
Bead Block 300-500 um, Weight Management, Lupron - Prostate Adenocarcinoma, Obesity, Morbid
Phase 2WithdrawnSidney Kimmel Comprehensive Cancer Center at Johns Hopkins2020-11-162022-05-02
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone - Perinatal Depression, Post Partum Depression
Phase 2CompletedUniversity of North Carolina, Chapel Hill232020-01-022023-08-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
REGN2810, Degarelix, Leuprolide Acetate - Prostate Cancer Metastatic
Phase 2Active not recruitingMark Stein262019-05-162025-04-25
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma
Phase 2Active not recruitingCity of Hope Medical Center252018-08-292026-04-09
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
5-Azacitidine, all trans retinoic acid, Lupron - Prostatic Neoplasms, Prostate Neoplasms
Phase 2CompletedIcahn School of Medicine at Mount Sinai142018-08-202024-04-30
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer
Phase 2RecruitingThe Methodist Hospital Research Institute602018-08-022021-04-06
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Apalutamide, Leuprolide, Prednisone - Prostate Cancer
Phase 2CompletedDana-Farber Cancer Institute1182016-10-192025-06-13
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Leuprolide acetate, Apalutamide, Radical prostatectomy - Prostate Cancer
Phase 2CompletedCase Comprehensive Cancer Center542016-10-172022-06-21

Showing 20 of 50. Sign in to see all of them.

Conditions studied

Prostatic Neoplasms (33)  ·  Breast Neoplasms (2)  ·  Depression, Postpartum (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Multiple Myeloma (2)  ·  Myelodysplastic Syndromes (2)  ·  Neoplasms (2)  ·  Depression (1)  ·  Eye Neoplasms (1)  ·  Granulosa cell tumor of the ovary (1)  ·  Hodgkin Disease (1)  ·  Insulin Resistance (1)  ·  Leukemia (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  M.D. Anderson Cancer Center (5)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  City of Hope Medical Center (3)  ·  Mayo Clinic (3)  ·  University of Washington (3)  ·  Dana-Farber Cancer Institute (2)  ·  Icahn School of Medicine at Mount Sinai (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Abbott (1)  ·  Baptist Health South Florida (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Case Comprehensive Cancer Center (1)  ·  Emory University (1)  ·  Jonsson Comprehensive Cancer Center (1)

Countries

United States (48)  ·  Canada (2)  ·  Czechia (1)

Top investigators

Celestia Higano, MD (2)  ·  Christopher Logothetis (2)  ·  Samuel Denmeade, MD (2)  ·  Alan L Ho (1)  ·  Amado Zurita, MD (1)  ·  Amar Kishan (1)  ·  Ann Partridge, MD (1)  ·  Anne R. Cappola, MD, ScM (1)  ·  Ashutosh K Tewari, MD (1)  ·  Catherine Marshall, M.D. (1)  ·  Christopher G Kanakry, M.D. (1)  ·  Crystal E Schiller, PhD (1)  ·  Cy A Stein (1)  ·  Dimple Chakravarty, PhD (1)  ·  Douglas McNeel, MD (1)

Results publications

PMID 19012911, PMID 20818327, PMID 22006050, PMID 25242417, PMID 25847934, PMID 29248669, PMID 33496795, PMID 33683939, PMID 37922910, PMID 38161319, PMID 38494380, PMID 39074346, PMID 39670843, PMID 40907514, PMID 41706486, PMID 42070324, PMID 42574969

NIH funding

P30CA015083 (2), P30CA033572 (2), K23AG019161 (1), N01CM00039 (1), N01CM62201 (1), N01CM62202 (1), N01CM62205 (1), N01CM62206 (1), P30CA008748 (1), P30CA015704 (1), P30CA016672 (1), P30CA022453 (1), P30CA138292 (1), P30DK019525 (1), P50CA272391 (1)